Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK) will present at LSI USA ’26 in Dana Point, California, March 16–20, 2026. The company presentation is scheduled for Tuesday, March 17 at 8:15 a.m. PT.
CEO Paul V. Goode, PhD, will introduce Glucotrack’s continuous blood glucose monitor (CBGM) technology, share positive first-in-human study results, and outline regulatory and U.S. commercialization plans toward a clinical trial, emphasizing a fully implantable, patient-centric device designed to reduce daily burden for people with diabetes.
Positive
- None.
Negative
- None.
News Market Reaction – GCTK
On the day this news was published, GCTK declined 2.37%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $34K from the company's valuation, bringing the market cap to $1M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While GCTK was down 5.03% pre-news, scanner peers showed mixed moves (e.g., NXGL up 7.12%, MLSS down 4.73%), and same-industry names like EKSO, LUCY, FEMY, MHUA, and HBIO also moved in differing directions, supporting a stock-specific backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Patent grants | Positive | -33.4% | USPTO issued three patents covering key components of CBGM platform. |
| Dec 30 | Private placement | Negative | -10.8% | At-the-market $4.0M private placement with new shares and warrants. |
| Nov 13 | Earnings update | Negative | -8.6% | Q3 2025 results with $15.8M nine-month net loss and going concern language. |
| Nov 03 | Shareholder vote call | Negative | -5.9% | Special meeting to approve highly dilutive $20M equity line and warrants. |
| Oct 29 | Advisory addition | Positive | -0.3% | Added PDN expert and reported long-term preclinical CBGM feasibility data. |
Recent news, even when operationally positive, has often coincided with negative price reactions, while financing and dilution-related items have generally aligned with downside moves.
Over the last several months, Glucotrack reported multiple financing and dilution-related developments alongside progress for its implantable CBGM platform. Patent issuances and advisory appointments in late 2025 highlighted technical and clinical advancement, yet shares fell after these updates. Private placement and equity-line related news, plus Q3 2025 results emphasizing losses and going-concern language, also saw negative reactions. Today’s conference presentation notice continues the theme of showcasing first-in-human CBGM data and regulatory plans against a backdrop of capital structure overhang and prior dilutive transactions.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-01-13 registers 3,224,803 resale shares from a December 2025 private placement, equal to about 354% of the 910,688 shares outstanding as of January 12, 2026. The company will not receive proceeds from these resales, but the large registered block and existing 424B3 usage indicate significant potential dilution and stock overhang for common shareholders.
Market Pulse Summary
This announcement highlights Glucotrack’s plans to present its continuous blood glucose monitor technology and positive first-in-human results at a major medtech summit, along with its regulatory and commercialization strategy toward a U.S. clinical trial. In the background, recent SEC filings describe sizeable potential dilution from 3,224,803 registered resale shares and ongoing losses noted in the latest 10-Q. Investors may watch for further clinical milestones, financing developments, and updates on regulatory timelines.
Key Terms
continuous blood glucose monitor medical
cbgm medical
first-in-human medical
clinical trial medical
AI-generated analysis. Not financial advice.
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA ’26 Summit, taking place March 16-20, 2026, in Dana Point, California.
The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack’s continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization strategy toward a U.S. clinical trial, and highlight the substantial unmet needs in diabetes management that the CBGM is designed to meet.
“By focusing on solutions that minimize disruption to daily life, our CBGM approach is intended to provide a less burdensome and more user‑friendly experience for people managing diabetes, supporting broader adoption and aligning with key market needs,” said Paul V. Goode, PhD. “LSI provides an ideal forum to engage with investors and partners who share this vision and can help bring to market a fully implantable, patient-centric device that sets new standards in convenience and patient independence.”
To register for the summit and schedule a one-on-one meeting with Dr. Goode, please visit: https://www.lsiusasummit.com/.
About Glucotrack, Inc.
Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system designed to continually measure blood glucose levels with a sensor longevity of up to three years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
When will Glucotrack (GCTK) present at LSI USA ’26 and what time is the presentation?
What will Paul V. Goode present about Glucotrack’s CBGM at LSI USA ’26 (GCTK)?
Does Glucotrack (GCTK) report clinical results during the LSI USA ’26 presentation?
How can investors or partners meet Glucotrack (GCTK) leadership at LSI USA ’26?
What strategic topics will Glucotrack (GCTK) cover about commercialization and regulatory path?
